Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
J Hum Genet. 2012 Aug;57(8):494-9. doi: 10.1038/jhg.2012.55. Epub 2012 Jun 14.
Prostaglandin E2 receptor subtype EP4 (PTGER4) is one of the four subtypes of receptors for prostaglandin E2 (PGE2). Overproduction of cysteinyl leukotriene in mast cells may be related with suppression of PGE2 in patients with aspirin hypersensitivity. Considering the association of PTGER4 in mast cells, urticaria- and aspirin-related disease, we hypothesized the genetic variability of PTGER4 may be associated with aspirin-intolerant chronic urticaria (AICU). The case-control study was performed in 141 with AICU, 153 with aspirin-tolerant chronic urticaria (ATCU) and 174 with normal controls (NCs). PTGER4 promoter single-nucleotide polymorphism was genotyped using a primer extension method with the SNAPshot ddNTP primer extension kit. The functional variability of PTGER4 promoter polymorphism was carried out by dual-luciferase system and electrophoretic mobility shift assay (EMSA) in human mast cells (HMC-1). Furthermore, the effect of aspirin was performed for PTGER4 mRNA expression using real-time PCR, and PGE2 production was checked in HMC-1 cells using ELISA. AICU patients carrying GG genotype at -1254 G>A showed significantly higher frequency compared with NC (P=0.032). Similarly, the minor allele frequency, G allele was significantly higher in AICU compared with NC (P=0.031). In vitro functional study demonstrated that the -1254 G allele had lower luciferase activity (P<0.001) in HMC-1 cells. EMSA finding showed that PTGER4 -1254 G produced a specific band. Significantly decreased PTGER4 expression (P=0.008) and PGE2 production by aspirin exposure was confirmed in in vitro HMC cell line model (P=0.001). The PTGER4 -1254 G allele demonstrated a higher frequency in AICU patients and lower promoter activity with decreased expression of PTGER4 and contributes to the development of AICU.
前列腺素 E2 受体亚型 EP4(PTGER4)是前列腺素 E2(PGE2)的四种受体亚型之一。肥大细胞中半胱氨酰白三烯的过度产生可能与阿司匹林过敏患者 PGE2 的抑制有关。考虑到 PTGER4 在肥大细胞、荨麻疹和阿司匹林相关疾病中的关联,我们假设 PTGER4 的遗传变异可能与阿司匹林不耐受性慢性荨麻疹(AICU)有关。这项病例对照研究纳入了 141 例 AICU 患者、153 例阿司匹林耐受性慢性荨麻疹(ATCU)患者和 174 例正常对照者(NC)。采用引物延伸法结合 SNAPshot ddNTP 引物延伸试剂盒对 PTGER4 启动子单核苷酸多态性进行基因分型。通过双荧光素酶系统和电泳迁移率变动分析(EMSA)在人肥大细胞(HMC-1)中检测 PTGER4 启动子多态性的功能变异性。此外,采用实时 PCR 检测阿司匹林对 PTGER4 mRNA 表达的影响,并用 ELISA 检测 HMC-1 细胞中 PGE2 的产生。与 NC 相比,-1254 G>A 处携带 GG 基因型的 AICU 患者的频率显著更高(P=0.032)。同样,AICU 中 minor 等位基因频率,G 等位基因也显著高于 NC(P=0.031)。体外功能研究表明,-1254 G 等位基因在 HMC-1 细胞中的荧光素酶活性较低(P<0.001)。EMSA 研究结果显示,PTGER4-1254 G 产生了一个特异性条带。在体外 HMC 细胞系模型中,经阿司匹林处理后 PTGER4 的表达明显降低(P=0.008),PGE2 的产生也减少(P=0.001)。AICU 患者中 PTGER4-1254 G 等位基因的频率更高,启动子活性降低,PTGER4 的表达减少,这可能导致 AICU 的发生。